NCT00318136 - A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Bevacizumab

15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3

DRUG

Carboplatin

Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles

DRUG

Paclitaxel

Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles